Search results
Results from the WOW.Com Content Network
Breakthrough Alzheimer’s treatments that remove toxic proteins from the brain have revived interest in vaccines to treat the memory-robbing disease, potentially offering a cheaper, easy-to ...
‘If the vaccine could prove successful in humans, it would be a big step forward towards delaying disease progression’ New vaccine could be key to preventing Alzheimer’s disease, scientists ...
UB-311 is a vaccine targeting β-amyloid and hence anti-amyloid agent which is under development for the treatment of Alzheimer's disease. [2] [3] It is under development by Vaxxinity. [2] Meningoencephalitis has been described as a possible side effect of the drug. [4] As of February 2024, the drug is in phase 2 clinical trials. [2]
Aducanumab, sold under the brand name Aduhelm, is an anti-amyloid drug designed to treat Alzheimer's disease. [2] [3] It is a monoclonal antibody [3] [2] that targets aggregated forms (plaque) [4] [5] of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup.
A new Alzheimer's drug, combined COVID and flu vaccine update, and salmonella concerns. 3 health stories you may have missed — and why they matter Kaitlin Reilly June 15, 2024 at 9:50 AM
Protollin is a drug initially formulated as a vaccine adjuvant. [ 1 ] [ 2 ] It is composed of lipopolysaccharides derived from the Shigella flexneri or Pleisiomonas shigelloides bacterium combined with hydrophobic outer membrane proteins derived from Neisseria meningitidis .
Alzheimer’s disease is the most common cause of dementia in the UK
The introduction of the original, 7-valent version of the vaccine, developed by Wyeth in February 2000, led to a 75% reduction in the incidence of invasive pneumococcal infections among children under age 5 in the United States. Pfizer introduced an improved version of the vaccine in 2010, for which it was granted a patent in India in 2017.